Rood & Riddle joins Equine Care Group in strategic partnership
Bottom line
Rood & Riddle Equine Hospital and Belgium-based Equine Care Group have announced a long-term strategic partnership aimed at expanding collaboration in clinical care, research, education, and innovation, while keeping Rood & Riddle’s name, leadership, culture, and clinical autonomy in place. Rood & Riddle said its current partners will become shareholders in the broader Equine Care Group, and both organizations framed the deal as a veterinarian-led partnership rather than a traditional consolidation play. The agreement was announced September 9, 2026, and is expected to close in the coming weeks, pending legal documentation, regulatory filings, and approvals. (roodandriddle.com)
Why it matters: For equine veterinarians, the significance is less about day-to-day client-facing change and more about access to a larger transatlantic clinical network. The organizations say the partnership should expand opportunities for complex case collaboration, research, continuing education, and knowledge-sharing across North America and Europe, including access to expertise in areas such as reproduction, diagnostics, nutrition, and specialized hospital care. Equine Care Group has been building a U.S. footprint this year, including its April 2026 partnership with Salado Equine Medical Center in Texas, so Rood & Riddle’s addition signals a bigger push into the American equine referral market. (roodandriddle.com)
What to watch: Watch for deal closing details, any regulatory filings, and early signs of how the partnership translates into shared research, education programs, referral collaboration, or recruiting efforts. (gimv.com)
Rood & Riddle Equine Hospital, one of the best-known equine hospitals in the U.S., is entering a long-term strategic partnership with Equine Care Group, a Belgium-founded veterinarian-led network that has been expanding internationally. The organizations said the move is designed to advance equine medicine through closer collaboration in patient care, research, education, and innovation, while preserving Rood & Riddle’s local leadership, identity, and clinical autonomy. The deal was announced September 9, 2026, and has not yet fully closed. (roodandriddle.com)
The announcement fits into a broader shift in equine practice structure, especially as large specialty and referral groups look for scale, talent, and research capacity without alienating clinicians or clients. Equine Care Group has explicitly positioned itself as a veterinarian-led alternative to more corporate models. In its April 2026 U.S. partnership with Salado Equine Medical Center, the group said its approach was “partnership, not acquisition,” and emphasized preserving identity and medical leadership at the local-practice level. (equimanagement.com)
Rood & Riddle’s own FAQ makes a similar case to clients and referring veterinarians. The hospital said horses will continue to be treated by the same veterinary teams, at the same locations, with no immediate changes to emergency services, specialty care, pricing, or record handling. It also disclosed a key structural detail: Rood & Riddle’s current partners will become shareholders in Equine Care Group, suggesting a deeper financial alignment than a loose collaboration agreement, even as public-facing messaging stresses continuity. (roodandriddle.com)
On the Equine Care Group side, investor-backed partner Gimv described Rood & Riddle as the largest privately owned equine hospital in the United States and said the parties had signed a partnership agreement, with closing expected in the coming weeks after customary legal documentation, regulatory filings, approvals, and other conditions. Financial terms were not disclosed. That language suggests a formal transaction process, even if the organizations are intentionally avoiding the optics of a conventional sale. (gimv.com)
Public commentary from leaders on both sides reinforces the strategic rationale. In a LinkedIn video post highlighted by Equine Care Group, Rood & Riddle CEO Deborah Spike-Pierce said the partnership came down to aligning missions and supporting the next generation of equine veterinarians. In a related podcast transcript, Equine Care Group founder Tom Mariën said he created the group after rejecting a more financially driven acquisition model, arguing that equine medicine should be directed by veterinarians and that collaboration is necessary to improve both clinical standards and quality of life for equine practitioners. Those comments are self-interested, but they help explain why both organizations are leaning so heavily on the veterinarian-led message. (linkedin.com)
Why it matters: For veterinary professionals, this partnership is most meaningful as a signal about where high-end equine medicine may be heading. If the model works as described, Rood & Riddle clinicians could gain broader access to international specialty expertise, shared research infrastructure, and cross-border education opportunities without losing local decision-making authority. That could matter in recruitment, retention, caseload management, and subspecialty development, particularly in a field where staffing pressure and succession planning remain persistent concerns. It may also put competitive pressure on other equine referral groups to sharpen their own value proposition around autonomy, collaboration, and career development. (roodandriddle.com)
There’s also a business implication for the wider veterinary market. Equine Care Group’s Texas deal in April 2026 marked its first U.S. partnership; landing Rood & Riddle just months later is a much bigger statement. It suggests the group is moving quickly from proof of concept in the U.S. to alignment with one of the sector’s most visible brands. For practices watching the consolidation landscape, this may be read as evidence that veterinarian-led, investor-backed hybrid structures are becoming more attractive, or at least more competitive, in equine medicine. That last point is an inference from the pace and profile of ECG’s U.S. moves, rather than something either company stated directly. (gimv.com)
What to watch: The next milestones are closing of the transaction, any required regulatory disclosures, and concrete evidence that the partnership produces more than branding, such as shared research projects, clinician exchanges, education initiatives, referral pathways, or new service-line investment across the combined network. (gimv.com)